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910Higher Nevus Count Exhibits a Distinct
DNA Methylation Signature in Healthy
Human Skin: Implications for Melanoma
Leonie Roos1,2,3, Johanna K. Sandling4, Christopher G. Bell1,5,6,7, Daniel Glass1, Massimo Mangino1,
Tim D. Spector1, Panos Deloukas8, Veronique Bataille1,9 and Jordana T. Bell1,9High nevus count is the strongest risk factor for melanoma, and although gene variants have been discovered
for both traits, epigenetic variation is unexplored. We investigated 322 healthy human skin DNA methylomes
associated with total body nevi count, incorporating genetic and transcriptomic variation. DNA methylation
changes were identified at genes involved in melanocyte biology, such as RAF1 (P ¼ 1.2  106) and CTC1
(region: P ¼ 6.3  104), and other genes including ARRDC1 (P ¼ 3.1  107). A subset exhibited coordinated
methylation and transcription changes within the same biopsy. The total analysis was also enriched for
melanoma-associated DNA methylation variation (P ¼ 6.33  106). In addition, we show that skin DNA
methylation is associated in cis with known genome-wide association study single nucleotide polymorphisms
for nevus count, at PLA2G6 (P ¼ 1.7  1049) and NID1 (P ¼ 6.4  1014), as well as melanoma risk, including in or
near MC1R, MX2, and TERT/CLPTM1L (P < 1  1010). Our analysis using a uniquely large dataset comprising
healthy skin DNA methylomes identified known and additional regulatory loci and pathways in nevi and
melanoma biology. This integrative study improves our understanding of predisposition to nevi and their
potential contribution to melanoma pathogenesis.
Journal of Investigative Dermatology (2017) 137, 910e920; doi:10.1016/j.jid.2016.11.029INTRODUCTION
The total body number of melanocytic nevi is the strongest risk
and predictive factor for melanoma in Caucasian populations
(Gandini et al., 2005; Olsen et al., 2009). Melanoma is the
most aggressive of skin tumors with an increasing incidence
(Siegel et al., 2014). These malignancies arise from an existing
benign nevus in 20% to 50% of cases (Haenssle et al., 2016;
Purdue et al., 2005; Shitara et al., 2014; Weatherhead et al.,
2007). The vast majority of nevi never progress to mela-
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an omelanoma arising de novo (Chang et al., 2009). Therefore,
further understanding of the biology of nevi will give insights
into the development and pathology of melanoma.
Typically, the number of nevi decrease after the age of 40;
however, in individuals at high risk of melanoma, this loss of
nevi is delayed, reflecting an altered senescence (Newton
et al., 1993). Furthermore, a higher total body nevus count
has also been associated with longer telomere length in
blood in individuals from the TwinsUK cohort (Bataille et al.,
2007). This link with senescence may indicate that the total
numbers of nevi reflect differences in senescence pathways
between individuals that can be detected in skin tissue where
nevi are found. The usefulness of nevus counts as an inter-
mediate phenotype to melanoma has already been shown in
genome-wide association studies (GWAS), as common single
nucleotide polymorphisms (SNPs) in the loci PLA2G6 and
MTAP were first associated with total body nevus count
(Falchi et al., 2009; Nan et al., 2011) and then subsequently
with melanoma risk (Barrett et al., 2011; Bishop et al., 2009).
For nevus count, variants in PLA2G6 were replicated across
two studies that also identified additional associations in
NID1, c11orf74, andMTAP. Although GWAS have identified
genetic variation for nevi count and melanoma, the variance
in nevus counts explained by these genes is low and no study
has previously examined epigenetic variation in this context.
Here, we explore epigenome-wide DNA methylation
variation in healthy human skin tissue in relation to total body
nevus counts in 322 female individuals from the TwinsUK
cohort. The focus of this study is on the potential to identify a
predisposing DNA methylation signature in normal skin to
the number of nevi and not the malignant changes occurring
in melanocytes themselves. It has become increasinglys. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Global DNA methylation profiles and skin tissue specificity. First
two principal components colored by layer specificity; red for dermal tissue,
blue for epidermal tissue, and yellow for our data (see the legend).
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Nevus Count Methylation Signature in Healthy Skinacknowledged that crosstalk between all cells within the skin
and melanocytes is important in the progression to mela-
noma (Kaur et al., 2016; Kim et al., 2013; Li et al., 2003; Shih
et al., 1994). We investigated individual CpG differentially
methylated positions (DMPs), as well as differentially meth-
ylated regions (DMRs) in healthy skin tissue, and corre-
sponding gene expression changes within the same tissue. To
study the potential interaction between genetic variants and
DNA methylation, we examined the association between the
skin DNA methylome and genetic variants previously asso-
ciated with nevus count or melanoma risk by GWAS.
RESULTS
The skin DNA methylome and its tissue layer specificity
As expected, because of the differing cell types in skin within
the dermis and epidermis, these tissue layers harbor distinct
DNAmethylation profiles (Vandiver et al., 2015). In our study,
skin tissue DNA was derived from a periumbilical punch bi-
opsy (adipose tissue was removed from the biopsy before
freezing) from 322 healthy female twins and profiled using the
InfiniumHumanMethylation450 BeadChip. To confirmwhich
skin layer was represented in our biopsy sample, we
compared our DNA methylation dataset with recently pub-
lished DNA methylation profiles of mechanically separated
epidermal (36 individuals) and dermal tissue (36 individuals)
from Vandiver et al. (2015). Principal component analysis was
performed on unadjusted DNA methylation profiles of the
three groups of samples (dermis [n ¼ 40], epidermis [n ¼ 38],
and our whole skin sample [n ¼ 322]). The first two principal
components explain 55.6% of the variance, capturing the skin
layer specificity of the dermis and epidermis samples aspreviously shown (Vandiver et al., 2015). Our whole skin
DNA methylation profiles cluster closely with the dermal
layer DNA methylation profiles (Figure 1).
Single CpG site differential skin DNA methylation in relation
to total body nevus count
We first explored evidence for differential skin DNA
methylation associated with total body nevus count at the
single CpG-site level across the genome in 322 healthy fe-
male twins. We fitted a linear mixed effects model regressing
DNA methylation levels on fixed effects (age, body mass in-
dex [BMI], smoking status, chip, order on the chip, and
bisulfite conversion efficiency) and random effects (family
structure and zygosity). Three DMPs were identified to be
significantly associated with total body nevus count (n-DMPs)
at a false discovery rate (FDR) of 5% and a further 45 asso-
ciations were observed at an FDR of 10% (Figure 2a, Table 1,
Supplementary Table S1 online). The 48 n-DMPs are
enriched for strong enhancers (ChromHMM state 4) in the
normal human epidermal keratinocyte cell line derived from
epidermal keratinocytes (P ¼ 0.03) and for CpG island (CGI)
shores (2 kb either side of the CGI, P ¼ 0.04), while depleted
for signals located in open sea genomic regions that are more
than 4 kb beyond CGIs (P ¼ 2.2  103).
The strongest signals are shown Table 1 and Figure 2b. The
most associated signal (cg06244240, P ¼ 5.5  108) lies in
a CGI shore approximately 6.5 kb downstream of METRNL,
which is expressed in skin (Ushach et al., 2015) and is also
involved in neural cell formation. The second ranked signal
(cg06123942, P ¼ 2.2  107) is in the 50 CGI promoter of
C15orf48, which displays reduced expression in squamous
cell carcinoma (Freiberger et al., 2015). The third ranked
signal (cg25384157, P ¼ 3.1  107) is positively associated
with the number of nevi and is in a CGI shore approximately
1.5 kb upstream of the transcription start site of ARRDC1, a
negative regulator of the Notch signaling pathway (Puca
et al., 2013). The CpG (cg11297934, P ¼ 1.2  106) lies
approximately 200 bp upstream of the transcription start site
of proto-oncogene RAF1 (also known as CRAF), which is a
member of the RAF family in the extracellular signal-
regulated kinase/mitogen-activated protein kinase pathway
that includes the key player BRAF.
Six of our top 10 n-DMPs did not show direct association
with age (P ¼ 0.05) including two of the top four results
(ARRDC1 and RAF1), with no n-DMP associations with age
surpassing FDR 10% correction (Figure 2c). The remaining
four signals did not show stronger evidence for association
with age alone compared with nevus count. These results
suggest that the majority of top-ranked n-DMPs are not
directly associated with age.
Regional differential skin DNA methylation associated with
total body nevus count
We next aimed to identify DMRs, that is, small genomic
regions that contain multiple CpG sites and show consistent
directional association with total body nevus count
(n-DMRs). DMRs have been found in general to be enriched
for functionally relevant regions as well as for GWAS SNPs
from the GWAS catalog (Ziller et al., 2013). We applied
the BumpHunter (Jaffe et al., 2012) algorithm and identifiedwww.jidonline.org 911
200
150
100
50
0
0.3 0.4 0.5
To
ta
l b
od
y 
ne
vu
s 
co
un
t
cg06123942 in C15orf48
Normalised unadjusted DNA methylation values
Age Nevus
Color Key
–log10 p value
2 4 6
0.05 0.10 0.200.15 0.25
cg25384157 in ARRDC1
0.150.10 0.250.20 0.30
6
4
FDR 10%
FDR 5%
2
0
1 2 3
-
lo
g1
0(P
)
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Chromosome
b
c
a
cg06244240 near METRNL
cg06244240
cg06123942
cg25384157
cg11297934
cg14762973
cg15977816
cg03755177
cg01880437
cg02683509
cg18401367
cg11074933
cg03163343
cg20093198
cg06569947
cg09536336
cg25343280
cg21068480
cg22534759
cg00347643
cg02236913
cg25720825
cg23082845
cg14278345
cg10139717
cg10929758
cg06739855
cg02496234
cg09456289
cg03315230
cg07821574
cg22985929
cg04685954
cg20193802
cg21220374
cg19179973
cg04587829
cg01505254
cg25369015
cg22494876
cg13631572
cg03166286
cg15375596
cg22617002
cg18421356
cg13650689
cg10339152
cg02208506
cg12836303
Figure 2. Nevus count epigenome-
wide results in 322 female
individuals. (a) Manhattan plot of the
epigenome-wide association results in
322 female individuals, where each
point represents the observed elog10
P-value at a CpG site. (b) Panel plot
depicting the direction of association
at the three top-ranked signals for
cg06244240 (left), cg06123942
(middle), and cg25384157 (right).
Results are plotted using normalized
unadjusted beta values per individual.
The lines represent the linear
correlation between DNA methylation
and total body nevus count. (c)
Heatmap of top 48 ranked n-DMPs
colored by elog10 P-values of age
association and nevus association.
DMP, differentially methylated
position.
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91248 n-DMRs (P < 0.01) genome-wide (Table 2, Supplementary
Table S2 online).
Subsequently, we examined the genomic context of the
n-DMRs. The strongest signal (P ¼ 6.8  105, Figure 3a) was
observed overlapping the 50 CGI promoter of ARRDC1. This
n-DMR includes the third ranked FDR 5% individual CpGJournal of Investigative Dermatology (2017), Volume 137n-DMP (cg25384157). We also identified an n-DMR in CTC1
that shows consistent negative association with total body
nevus count amongst its three CpG sites (Figure 3b). It is in a
region with active promoter evidence across multiple
ENCODE cell types including normal human epidermal
keratinocytes, which resides in the three prime untranslated
Table 1. Most associated nevus differentially methylated positions (n-DMPs)
Rank CpG Position (hg19) Associated gene Location CpG island Beta St. error P-value FDR
1 cg06244240 chr17: 81058948 e e Shore 0.0052 0.0009 5.52  108 5%
2 cg06123942 chr15: 45722795 C15orf48 50UTR Island 0.0074 0.0014 2.20  107 5%
3 cg25384157 chr9: 140499131 ARRDC1 TSS1500 Shore 0.0063 0.0012 3.06  107 5%
4 cg11297934 chr3:12705868 RAF1 TSS200 Island 0.0046 0.0009 1.16  106 10%
5 cg14762973 chr2:187714067 ZSWIM2 TSS200 Island 0.0069 0.0014 1.49  106 10%
Abbreviations: FDR, false discovery rate; TSS, transcription start site; UTR, untranslated region.
Table 2. Most associated nevus differentially methylated regions (n-DMRs)
Rank Position (hg19)
Associated
gene Location
CpG
island
Number of
CpG sites
DNA
methylation P-value
Overview direction
CpG sites
1 chr9:140499132e140500813 ARRDC1 TSS1500-Body Island 7 þ 2.5  105 þ þ    þ þ
2 chr10:14647154e14647530 FAM107B Body Shore 3 þ 2.5  104 þ þ þ
3 chr19:44285297e44285568 KCNN4 TSS200-1stExon e 3 þ 2.9  104 þ þ þ
4 chr17:8129997e8130356 CTC1 30UTR Shelf 3 e 6.3  104   
5 chr15:26915414e26915752 GABRB3 Body Island 3 e 8.3  104   
Abbreviations: TSS, transcription start site; UTR, untranslated region.
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lincRNA LINC00324. CTC1 is a component of the CTS
(CTC1, TEN1, and STN1) complex that has a pivotal role in
protecting telomeres from degradation.
Nevus differential methylation signatures reflected in gene
expression changes
We then explored individual CpG sites in the 48 n-DMRs for
association with gene expression levels using transcription
profiles available in 248 individuals using the same skin bi-
opsy as for DNA methylation profiling. The analysis focused
on CpG sites that showed the same direction of effect in the
n-DMR as in the single CpG site epigenome-wide association
study (EWAS). We analyzed gene expression data at 36 genes
for 27 n-DMRs, where the n-DMRs were either located in or
were within 20 kb of the gene (Supplementary Table S3 on-
line). Both DNA methylation and expression levels were
adjusted for similar covariates and corresponding technical
covariates and compared with Pearson correlation. At least
one CpG site in 12 unique n-DMRs was shown to be corre-
lated with the expression levels of 14 unique genes at nom-
inal significance (P ¼ 0.05, Supplementary Table S3). This
included one of the three CpG sites forming the third ranked
n-DMR in KCNN4 (cg15977816, r ¼ 0.19, P ¼ 2.9  103).
Strong n-DMRs that have more than one CpG site in the re-
gion correlated with one of more expression probes of the
same gene include n-DMRs at MED11, C14orf50, FAM64A,
KRT86, TTC15, and C6orf27.
Nevus DNA methylation signature is enriched for
melanoma-associated DNA methylation changes
Healthy tissue DNA methylomes can show risk-factor-related
signatures also found in malignant tissue (Noreen et al.,
2014). Furthermore, tumor methylation patterns have been
shown to derive from the continuum of maturation states that
are reflected in normal developmental stages (Oakes et al.,
2016). We therefore examined the DNA methylome data ofmelanomas to see whether our identified n-DMP signature
was enriched within this malignant tissue epigenome.
The most comprehensive melanoma DNA methylome
study to date is a comparison between normal melanocytes
from three donors and 27 metastatic melanoma DNA sam-
ples using methylated-CpG island recovery assay sequencing
by Jin et al. (2015). They reported 3,113 regions that were
hypermethylated in melanoma. Of these, 2,039 regions
contained at least one CpG site profiled in our dataset and
13.4% (274 regions, containing 406 CpG sites) of these were
identified as nominally significant with a positive association
with total body nevus count. Within CGIs, which the
methylated-CpG island recovery assay sequencing technique
targets, we observed an enrichment of hypermethylated
nominally significant CpG sites (Fisher’s P ¼ 6.33  106).
Another study, a genome-wide screen of promoter DNA
methylation (24,103 RefSeq promoters) between normal skin,
nevi, and advanced stage melanoma, identified four differ-
entially methylated genes (Koga et al., 2009). At two of these
genes, THBS1 and TNFRSF10D, we identified a positive
association between total body nevus count and promoter
CpG methylation, in line with their findings of increased
DNA methylation in advanced stage melanoma.
Impact of GWAS SNPs associated with total body nevus
count or melanoma risk on skin DNA methylation in cis
We next investigated the influence of genetic variants, previ-
ously associated inGWASwith nevus count ormelanoma risk,
on nearby DNAmethylation levels in skin tissue for a subset of
283 individuals. We selected 4 SNPs previously associated
with the number of cutaneous nevi (Falchi et al., 2009; Nan
et al., 2011) and 23 SNPs associated with melanoma risk
from the GWAS catalog (Welter et al., 2014), which fall within
100 kb of CpG sites available in our dataset. Mixed linear
models were performed to test for association accounting for
family structure and results are presented at a threshold of
P< 1.0 105. This is comparable with a genome-wide cutoff
at FDR 1%, as reported previously (P< 8.6 104), where allwww.jidonline.org 913
Figure 3. Location of two top-ranked n-DMRs in the human genome. Figures obtained from UCSC Genome browser, displaying position in the genome (hg19),
CpG sites from HumanMethylation450 BeadChip, n-DMR (in light blue), RefSeq genes, CpG island, transcription factor ChIP data, DNase-I sensitivity sites, and
ChromHMM genomic segmentation. (a) At ARRDC1. (b) At CTC1. DMR, differentially methylated region.
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914DNA methylation was assessed within 100 kb of common
genetic variants (Grundberg et al., 2013).
Thirteen SNPs were significantly associated with DNA
methylation changes in skin (P < 1  105, Table 3). These
included three of the four SNPs identified by GWAS to be
associatedwith total body nevus count: rs2284063 in intron of
PLA2G6 (cg25457927, P¼ 3.5 1038), rs3768080 in intron
of NID1 (cg18765906, P ¼ 6.4  1014), and rs738322 in
another intron of PLA2G6 (cg25457927, P¼ 1.7 1049). The
results also included 10 SNPs previously identified for mela-
noma risk reported at MC1R (2 SNPs), MX2, TERT/CLPTM1L,
PLA2G6, CASP8, ACTRT3, ASIP, CDC91L1, and ARNT/
SETDB1/LASS2ANXA9/MCL1/CTSK (Figure 4). Six of these
CpG sites occurred in active promoters or enhancers in normal
human epidermal keratinocytes (derived from epidermal ker-
atinocytes) (Ernst et al., 2011). None of the CpG sites associ-
ated with these SNPs were epigenome-wide statistically
significant n-DMPs orwithin n-DMRs fromour EWAS analysis.
However, nine nevus count CpG sites within these regions
were associated with nevus count at nominal significance
(P ¼ 0.05), including the result at PLA2G6.Journal of Investigative Dermatology (2017), Volume 137The 13 SNPs have not been previously reported
as expression quantitative loci (eQTLs) using the same
skin biopsy expression data (Grundberg et al., 2012).
However, results from the Genotype-Tissue Expression
Project (GTEx Consortium, 2015) datasets show that
eight of these SNPs are eQTLs in either skin tissue (sun or
not sun exposed) and/or transformed fibroblasts. These
GTEx eQTLs were associated with the expression of 16
genes in total, and at 7 of these we identified DNA
methylation variation associated with the same SNP:
CASP8 (rs1301693), MAFF, PLA2G6, TMEM184B, and
BAIAP2L2 (rs2284063, rs738322, and rs6001027),
SPATA33 (rs258322), MX2 (rs45430), and CDK10
(rs4785763).
DISCUSSION
To our knowledge, this is the first study to explore
epigenome-wide DNA methylation in the largest healthy
human skin tissue dataset to date, in relation to the number
of nevi, the strongest risk factor of melanoma. This analysis
adds an additional layer to our current understanding of
Table 3. Strongest CpG association per GWAS SNP
Trait SNP Position (hg19) Reported genes CpG beta P-value Associated gene Location CpG island
Distance to
SNP (kb)
Melanoma rs401681 chr5:1322087 TERT, CLPTM1L cg06550200 0.783 2.6  1050 CLPTM1L Body e 3.5
Cutaneous nevi rs738322 chr22:38569006 PLA2G6 cg25457927 0.851 1.7  1049 e e Shelf 26.4
Melanoma rs45430 chr21:42746081 MX2 cg22778903 0.711 1.9  1042 MX2 50UTR e 4.4
Melanoma rs6001027 chr22:38545619 PLA2G6 cg25457927 0.843 1.3  1038 e e Shelf 49.8
Cutaneous nevi
and Melanoma
rs2284063 chr22:38544298 PLA2G6 cg25457927 0.834 3.5  1038 e e Shelf 51.1
Melanoma rs7412746 chr1:150860471 ARNT, SETDB1, LASS2,
ANXA9, MCL1, CTSK
cg15448220 0.662 1.4  1032 SETDB1 TSS1500 Shore 37.4
Melanoma (2) rs258322 chr16:89755903 MC1R cg05714116 0.728 5.5  1014 CDK10 TSS1500 Shore 3.3
Cutaneous nevi rs3768080 chr1:236179869 NID1 cg18765906 0.374 6.4  1014 NID1 Body e 4.5
Melanoma rs4785763 chr16:90066936 MC1R cg08547343 0.346 1.0  109 CENPBD1;AFG3L1 50UTR; TSS200 Island 28.1
Melanoma rs910873 chr20:33171772 CDC91L1 cg01901788 0.441 1.8  106 MAP1LC3A TSS1500 Shore 25.9
Melanoma rs13097028 chr3:169464942 ACTRT3 cg27020690 0.289 2.0  106 e e Island 17.4
Melanoma rs13016963 chr2:202162811 CASP8 cg24599065 0.230 2.1  106 CASP10 30UTR e 69.0
Melanoma rs228437 chr6:134898456 ASIP cg24504307 0.355 9.2  106 e e e 64.7
Melanoma rs3219090 chr1:226564691 PARP1 cg18764804 0.240 6.2  104 PARP1 TSS1500 Shore 32.0
Melanoma rs1031925 chr3:51379274 DOCK3 cg09456445 0.315 8.5  104 DOCK3 30UTR Shore 41.1
Melanoma rs1722784 chr1:150961869 ANXA9 cg07479786 0.261 8.9  104 ANXA9 30UTR e 6.0
Melanoma rs16953002 chr16:54114824 FTO cg01083598 0.169 7.2  103 e e Island 41.2
Melanoma rs35390 chr5:33955326 SLC45A2 cg01990593 0.689 8.8  103 ADAMTS12 Body Shore 65.0
Melanoma rs1801516 chr11:108175462 ATM cg08954307 0.249 9.8  103 ATM Body e 59.3
Cutaneous nevi rs4636294 chr9:21747803 MTAP cg03724238 0.128 0.013 e e Island 51.1
Melanoma rs4698934 chr4:106139387 TET2 cg08530497 0.195 0.037 TET2 Body e 15.9
Melanoma rs1847134 chr11:89005253 TYR cg25941151 0.153 0.041 TYR TSS200 e 94.3
Melanoma (2) rs7023329 chr9:21816528 CDKN2A cg14548963 0.118 0.068 MTAP Body e 3.6
Melanoma (2) rs1393350 chr11:89011046 TYR cg03508346 0.118 0.142 NOX4 30UTR e 48.8
Melanoma rs17119461 chr10:107516352 NR cg18758405 0.290 0.333 e e e 65.0
Melanoma rs1889497 chr6:65432283 EYS cg11999886 0.026 0.760 EYS Body e 90.8
Abbreviations: GWAS, genome-wide association studies; SNP, single nucleotide polymorphism; TSS, transcription start site; UTR, untranslated region.
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916the genomic biology of nevi development on top of that
previously obtained via GWAS. We used normal skin bi-
opsies of 322 healthy female twins and showed that these
biopsies represent mostly homogenous dermis cells due to
their distinct epigenetic signature. We identified DNA
methylation variation associated with total body nevus
count at, to our knowledge, previously unreported genes
and also at known genes in nevi formation or melanoma,
both at single CpGs and regions. These top-ranked results
are significantly enriched for strong enhancers in normal
human epidermal keratinocyte cell lines as well as for CGI
shores, regions identified as more dynamic and functional
in both cancer (Irizarry et al., 2009) and stem cell
reprogramming (Doi et al., 2009). Approximately half
of the regional epigenetic changes tested also hadJournal of Investigative Dermatology (2017), Volume 137corresponding gene expression differences in the same
biopsy. Finally, we identified DNA methylation variation in
cis associated with known GWAS SNPs for both nevi
number and melanoma risk.
We identified many genomic loci that exhibited differ-
ential methylation associated with total body nevus count
that were highly relevant to melanocyte biology and can-
cer. Among these is the n-DMR at CTC1, involved in
telomere maintenance and associated with telomere
length (Mangino et al., 2012). Telomere length has been
positively associated with high nevus count and melanoma
risk (Bataille et al., 2007), as well as via a genetic score
analysis from seven telomere length associated SNPs (Iles
et al., 2014). This suggests that telomeres within healthy
skin may already be longer in high nevus count individuals
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has been shown between leukocytes and skin (Daniali
et al., 2013), and supports previous work in melanoma
biology. It may also explain why individuals with multiple
atypical nevi are relatively protected against photo-aging,
due to potential reduced skin senescence.
An important molecular pathway highlighted, due to
differential DNA methylation in RAF1, is the mitogen-
activated protein kinase/extracellular signal-regulated ki-
nase pathway that includes BRAF. BRAF mutations are
found in approximately 50% of all melanoma tumors and
are of significant clinical utility as major therapeutic de-
cisions are made according to the presence or absence of
mutations in this gene (Flaherty et al., 2010). Somatic mu-
tations in the oncogene RAF1 are remarkably rare in human
cancers (Emuss et al., 2005); however, in BRAF negative
melanomas, targeting RAF1 leads to apoptosis. Therefore,
the significant identification that this pathway is altered via
DNA methylation could lead to the re-evaluation of using
mutational status alone in advanced melanoma treatment
decisions (Heyn and Esteller, 2012).
Another result of note is ARRDC1, part of the highly
conserved cell signaling NOTCH pathway. This pathway is
pivotal in cell-fate determination across many organ systems
in embryogenesis and also tissue maintenance in adults.
Expression of Notch1 is low or not detectable in melano-
cytes as well as nevi; however, higher expression is associ-
ated with their transformation to melanoma (Massi et al.,
2006; Pinnix et al., 2009). ARRDC1 is necessary for Itch
E3 ubiquitin ligase-mediated NOTCH receptor degradation
(Puca et al., 2013).
We also found that our nevi signature was enriched for
DNA methylation changes previously identified in mela-
noma (Jin et al., 2015). This may indicate a priming or
predisposition to melanoma of normal skin with more
nevi. We then investigated the effect of 26 unique genetic
variants, previously associated by GWAS with nevus
number (4 SNPs) or melanoma risk (23 SNPs), on DNA
methylation within 100 kb (Falchi et al., 2009; Nan et al.,
2011; Welter et al., 2014). Half of these SNPs were
significantly associated with DNA methylation changes in
skin tissue. For all three GWAS SNPs reported for PLA2G6,
which is associated with both nevus numbers and mela-
noma, eQTLs have been reported in skin and/or trans-
formed fibroblasts impacting on the expression of PLA2G6,
MAFF, TMEM184B, and BAIAP2L2. All of these genes
harbored SNP-associated DNA methylation variation in
our study. This highlights the usefulness of integrating DNA
methylation analysis with robust GWAS discoveries to
identify functional pathways underlying strong genetic
signals. Furthermore, we identified GWAS SNP-associated
DNA methylation variation, not only in genes with known
eQTLs, but also in novel genes.
Compared with other studies, our sample is much larger
than previous skin DNA methylation studies (Roberson et al.,
2012; Rodrı´guez et al., 2014; Vandiver et al., 2015), and
we have profiled only women, who are known to have
different distributions of nevi on the body compared with
men (Autier et al., 2004) as well as sex-specific differences in
DNA methylation (Singmann et al., 2015). In addition, thisstudy benefits from the extensive data for nevus counts
collected by trained dermatology nurses of healthy in-
dividuals. In contrast to blood-based EWAS, this study also
highlights the strength of investigating the phenotype-
appropriate tissue to help understand biological pathways
implicated in disease.
To conclude, this study based on skin biopsies of
322 healthy female Caucasians using DNA methylome,
transcriptome, and GWAS data from the same individuals
identified DNA methylation differences associated with
the number of nevi. We identified pathways and genes
that add to our current understanding of the biology of
the number of nevi and the pathology of melanoma. These
data open up avenues for future exploration in skin,
not only why some individuals have higher numbers
of nevi but how this phenotype contributes to melanoma
risk.
MATERIALS AND METHODS
Sample selection
Detailed information regarding nevus count was obtained from
twins registered with the TwinsUK Adult Twin Registry. The twins
in this registry are not selected for diseases and were similar in
means and ranges of quantitative phenotypes to an age-matched
population in the UK (Andrew et al., 2001). Written informed
consent from all subjects was obtained in accordance with Guy’s
and St Thomas’ National Health Service Foundation Trust Ethics
Committee (EC04/015—15-Mar-04). The selected individuals did
not have a personal medical history of malignant melanoma or
other skin cancers obtained through record linkage with the
National Cancer Registry at the Office for National Statistics. The
examination was performed by trained research nurses following
a standardized and reproducible nevus count protocol as
described previously (Bataille et al., 2000). Total body nevus
count was the sum of all nevi >2 mm across 17 body sites.
DNA methylation data profiled from skin tissue were available
for 322 female twins with a mean age of 59 years, including 25
monozygotic twin pairs, 64 dizygotic twin pairs, and 144 unre-
lated individuals of European descent. Punch biopsies (8 mm)
were taken from a relatively photo-protected area adjacent and
inferior to the umbilicus and were mechanically dissected for
skin tissue removing the fat layer before freezing. Written
informed consent from all study subjects was obtained and the
procedures were in accordance with the ethical standards of the
St. Thomas’ Research Ethics Committee (REC reference 07/
H0802/84). The skin biopsy samples were obtained within 6.5
and 11.9 years after nevus count with a mean of 9.7 years
(Supplementary Figure S1 online).
Genome-wide DNA methylation profiles
Genome-wide DNA methylation profiles were obtained from 326
bisulfite-converted skin tissue DNA samples assayed by Illumina
Infinium HumanMethylation450 BeadChip (Illumnia, San Diego,
CA). DNA methylation levels were denoted as betas: the ratio of
intensity signal from the methylated probes over the sum of in-
tensity signals from both unmethylated and methylated probes.
Multiple measurements of analytical quality were applied. Probes
were removed for the main analyses that failed detection in at
least one sample or had a bead count less than 3 in more than 1%
of the samples (n ¼ 18,208), had a 50 bp probe sequence thatwww.jidonline.org 917
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918aligned to multiple locations in the genome (n ¼ 17,764),
harbored common genetic variants (minor allele frequency [MAF]
 1%) within 10 bp on the probe at the interrogated CpG site
(15,827), or contained variants at any MAF within 10 bp at the
interrogated CpG site (11,236), and were located on the sex
chromosomes (n ¼ 11,650). Probes with genetic variants within
the 50 bp of the CpG, but not within 10 bp, were not excluded for
GWAS SNP analyses but were highlighted as such in the figures
and accompanying text.
Individuals were verified using the 57 autosomal SNP probes
included as control probes on the BeadChip. Overall intensity signal
as well as bisulfite conversion efficiency was assessed and the data
were inspected visually for outliers using beta density plots, boxplots,
and imprinted regions (using the R package wateRmelon [Pidsley
et al., 2013]). Four individual samples were excluded based on low
mean intensity signals. The remaining 322 samples were normalized
using the beta mixture quantile dilation method to correct for probe-
type bias (Teschendorff et al., 2013). Principal component analysis
was performed on beta mixture quantile dilation normalized beta
values that were standardized (N(0,1)) at each probe. The first three
principal components, which when combined explain 36% of the
total variance, were assessed for associations with possible con-
founders for DNA methylation data including BeadChip, position on
the BeadChip, age, smoking status, BMI, and bisulfite conversion ef-
ficiency. Strongly significant associations (P < 1  1020) were
identified with BeadChip and bisulfite conversion efficiency.
Gene expression profiles
Gene expression profiles were obtained of the same skin tissue
biopsies that were profiled for DNA methylation for 248
individuals from the MuTHER project (Multiple Tissue Human
Expression Resource) as previously described (Grundberg et al.,
2012). In short, punch biopsies (8 mm) were taken from a
photo-protected area adjacent and inferior to the umbilicus of
which skin tissue was dissected. RNA was extracted and
expression profiling was performed using Illumina Human HT-12
V3 BeadChips. Probes with less than three beads present were
excluded and log2-transformed expression signals were normal-
ized separately per tissue, with quantile normalization of the
replicates of each individual followed by quantile normalization
across all individuals.
Genotypes
Genotype data of 283 individuals were available from the TwinsUK
dataset as previously described (Small et al., 2011), genotyped using
a combination of Illumina HumanHap300, HumanHap610Q, 1M-
Duo, or 1.2M-Duo custom arrays. Imputation was done based on
1000 Genomes data phase 3. Quality control measures included
minimum genotyping rate (>95%), Hardy-Weinberg equilibrium
(P > 106), minimum MAF (>1%), and imputation quality score
>0.5 for GWAS catalog SNPs. This subset of individuals included
only individuals of Caucasian ancestry.
Statistical analysis
DMPs associated with total body nevus count were identified using a
linear mixed effects model fitted on the normalized beta values per
probe (N(0,1)) with total body nevus count, age, BMI, smoking, bead
chip, position on the bead chip, and bisulfite conversion efficiency
as fixed effects, and family and zygosity as random effects. This
model was compared with a null model that excluded total body
nevus count by analysis of variance. Results were consideredJournal of Investigative Dermatology (2017), Volume 137genome-wide significant if they surpassed an FDR threshold of 5%
and considered suggestive when surpassing an FDR of 10%, esti-
mated using “qvalue” in R.
Nevus count DMPs were tested for association with age using a
linear mixed effects model fitted on the normalized beta values per
probe (N(0,1)) with age, BMI, smoking status, BeadChip, position on
the BeadChip, and bisulfite conversion efficiency as fixed effects,
and family and zygosity as random effects. This was compared with a
null model without age by analysis of variance to test for
significance.
Small DMRs associated with nevus count were identified using R
package “Bumphunter” (Jaffe et al., 2012). Regions required at least
three consecutive probes with a maximum gap of 500 bp between
each probe. DNA methylation was adjusted for covariates described
previously for DMP analysis before using Bumphunter. Nevus count
DMRs were considered with a P-value <0.01 estimated based on
1,000 permutations.
Gene expression analysis of the top-ranked DMRs was per-
formed in a sample of 248 individuals using the same skin tissue
biopsy used for DNA methylation profiling. A linear mixed model
was fitted on the expression data with age, BMI, smoking status,
batch, and concentration (fixed effects) and family and zygosity
(random effects) as well as the linear mixed model fitted for DNA
methylation data described previously for n-DMP analysis. The
residuals from both models were compared with Pearson
correlation.
Genotype variation analyses using GWAS SNPs were performed
in a sample of 283 individuals using genome-wide efficient mixed
model association to account for family structure present in the data
and adjusted DNA methylation levels for fixed covariates used in the
n-DMP analysis (age, BMI, smoking status, BeadChip, position on
the BeadChip, and bisulfite conversion efficiency).
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